Stockpolly
Search
SPRO · NASDAQ · Biotechnology

Spero Therapeutics (SPRO)

Develops SP001 while retaining economics linked to GSK-marketed Utebzi.

$1.22
At close+0.02 (+1.67%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue2574410131561234000
Cost of revenue1490240951400000
Gross profit25244−1413−80−81234000
27−2618632−58714118810
Research & development16171724272914119633
666657764456
Selling & marketing010001000000
General & administrative666656764456
Other expenses5−49−5−240−94−13−2−2−200
Operating income−251−14−19−19−22−15−2−831−8−10
111111111000
Interest income111111111000
Other non-operating income−5−1−1−1−1−100−1000
Income before tax−152−13−18−17−21−14−2−732−7−10
Income tax expense200000000000
Net income from continuing operations−351−13−18−17−21−14−2−732−7−10
Net income−351−13−18−17−21−14−2−732−7−10
EPS, basic−$0.06$0.97−$0.24−$0.33−$0.32−$0.39−$0.25−$0.03−$0.13$0.56−$0.13−$0.16
EPS, diluted−$0.06$0.96−$0.24−$0.33−$0.32−$0.39−$0.25−$0.03−$0.13$0.53−$0.13−$0.16
Weighted average shares, basic535354545454555656565758
Weighted average shares, diluted535354545454555656595758
EBITDA352−13−18−17−21−15−2−732−7−10
Depreciation & amortization000000000000
EBIT352−13−18−17−21−15−2−732−7−10